Clinical trial
CHAMP - An Open-label, Randomised, Multicentre, Phase II Clinical Study of Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Stage IIIB or IV Primary Nonsquamous Non-small Cell Lung Cancer, With Particular Regard to the KRAS Status
NCT01088620 is registered in ClinicalTrials.gov with WiSP Wissenschaftlicher Service Pharma GmbH as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- CHAMP - An Open-label, Randomised, Multicentre, Phase II Clinical Study of Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Stage IIIB or IV Primary Nonsquamous Non-small Cell Lung Cancer, With Particular Regard to the KRAS Status
- Lead sponsor
- WiSP Wissenschaftlicher Service Pharma GmbH
- Phase
- Phase 2
- Overall status
- Suspended
- Start date
- April 30, 2010
- Completion date
- January 31, 2014
- Enrollment
- 134 (estimated)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.